Cost-effectiveness of pembrolizumab plus axitinib as first-line therapy for advanced renal cell carcinoma

被引：5
|
作者：
Zhu, Jiaxin [1 ]
Zhang, Tiantian [1 ,2 ,3 ]
Wan, Ning [3 ,4 ]
Liang, Zhuoru [1 ]
Li, Jiahao [1 ]
Chen, Xudong [1 ]
Liang, Wenhua [5 ,6 ,7 ,8 ]
Jiang, Jie [1 ,2 ,9 ]
机构：
[1] Jinan Univ, Coll Pharm, Guangzhou, Peoples R China
[2] Jinan Univ, Int Cooperat Lab Tradit Chinese Med Modernizat &, Chinese Minist Educ MOE, Guangzhou, Peoples R China
[3] Guangzhou Huabo Biopharmaceut Res Inst, Guangzhou, Peoples R China
[4] Gen Hosp Southern Theatre Command, Dept Pharm, Guangzhou, Peoples R China
[5] Guangzhou Med Univ, Dept Thorac Surg & Oncol, Affiliated Hosp 1, Guangzhou, Peoples R China
[6] Guangzhou Inst Resp Dis, Guangzhou, Peoples R China
[7] China State Key Lab Resp Dis, Guangzhou, Peoples R China
[8] Natl Clin Res Ctr Resp Dis, Guangzhou, Peoples R China
[9] Jinan Univ, Dongguan Inst, Dongguan, Peoples R China
来源：
IMMUNOTHERAPY | 2020年 / 12卷 / 17期
基金：
中国国家自然科学基金;
关键词：
axitinib; cost-effectiveness; immunotherapy; Markov; pembrolizumab; renal cell carcinoma; sunitinib; tyrosine kinase inhibitor; NIVOLUMAB; SUNITINIB; SURVIVAL;
D O I：
10.2217/imt-2020-0034
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Aim: To evaluate the cost-effectiveness of first-line treatments for advanced renal cell carcinoma with pembrolizumab plus axitinib compared with sunitinib from the US payer perspective. Patients & methods: A Markov model was developed for this purpose. The clinical data were obtained from the KEYNOTE-426 trial. Utility values and direct costs related to the treatments were gathered from the published studies. Results: The incremental cost-effectiveness ratios of pembrolizumab plus axitinib versus sunitinib was $249,704 per quality-adjusted life year, which was higher than a willingness-to-pay threshold of $150,000 per quality-adjusted life year. Conclusion: Pembrolizumab plus axitinib was not considered to be cost-effective versus sunitinib as a first-line treatment for patients with advanced renal cell carcinoma from the US payer perspective.
引用
收藏
页码：1237 / 1246
页数：10
相关论文
共 50 条
  • [1] Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma
    Bensimon, Arielle G.
    Zhong, Yichen
    Swami, Umang
    Briggs, Allison
    Young, Joshua
    Feng, Yuan
    Song, Yan
    Signorovitch, James
    Adejoro, Oluwakayode
    Chakravarty, Abhiroop
    Chen, Mei
    Perini, Rodolfo F.
    Geynisman, Daniel M.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (09) : 1507 - 1517
  • [2] Cost-effectiveness of pembrolizumab in combination with axitinib as first-line treatment for advanced renal cell carcinoma
    Bensimon, Arielle G.
    Zhong, Yichen
    Swami, Umang
    Briggs, Allison
    Young, Joshua
    Feng, Yuan
    Song, Yan
    Signorovitch, James
    Adejoro, Oluwakayode
    Chakravarty, Abhiroop
    Chen, Mei
    Perini, Rodolfo F.
    Geynisman, Daniel M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [3] Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China
    Jun Chen
    Gaoyun Hu
    Zhuo Chen
    Xiaomin Wan
    Chongqing Tan
    Xiaohui Zeng
    Zeneng Cheng
    [J]. Clinical Drug Investigation, 2019, 39 : 931 - 938
  • [4] Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China
    Chen, Jun
    Hu, Gaoyun
    Chen, Zhuo
    Wan, Xiaomin
    Tan, Chongqing
    Zeng, Xiaohui
    Cheng, Zeneng
    [J]. CLINICAL DRUG INVESTIGATION, 2019, 39 (10) : 931 - 938
  • [5] Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US
    Watson, Tina R.
    Gao, Xin
    Reynolds, Kerry L.
    Kong, Chung Yin
    [J]. JAMA NETWORK OPEN, 2020, 3 (10)
  • [6] A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma
    Shay, Rebecca
    Nicklawsky, Andrew
    Gao, Dexiang
    Lam, Elaine T.
    [J]. CLINICAL GENITOURINARY CANCER, 2021, 19 (04) : 370 - +
  • [7] Cost-Effectiveness of Lenvatinib Plus Pembrolizumab or Everolimus as First-Line Treatment of Advanced Renal Cell Carcinoma
    Wang, Ye
    Wang, Hao
    Yi, Manman
    Han, Zhou
    Li, Li
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [8] COST-EFFECTIVENESS OF PEMBROLIZUMAB plus AXITINIB VERSUS NIVOLUMAB plus IPILIMUMAB AS FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN THE PRIVATE HEALTHCARE SYSTEM IN BRAZIL
    Garmatter, L. P. Leonart
    Berlinski, F.
    Rego, M. A. D. C.
    Bastos, D. A.
    Soares, A.
    Kater, F. R.
    Nunes, A. A.
    Santos, M.
    Riveros, B. Salgado
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S149 - S150
  • [9] A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma
    Lu, Peiyao
    Liang, Weiting
    Li, Jiahao
    Hong, Yanming
    Chen, Zhuojia
    Liu, Tao
    Dong, Pei
    Huang, Hongbing
    Zhang, Tiantian
    Jiang, Jie
    [J]. FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [10] Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
    Wu, Bin
    Zhang, Qiang
    Sun, Jie
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
12345